Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
about
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.Combination therapy with the type II anti-CD20 antibody obinutuzumab.The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trialsSpanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860
Q43924146-9189379E-90F2-482E-BDBC-22D3553B1681Q47898168-91E664AB-193F-4523-BBD4-7D98C434BA39Q49914090-4E470AA0-F77A-479A-A9EC-D09B6261278DQ53280595-4E469B54-6010-459A-B027-154668FCBE3AQ55283747-0B1CD1F4-6B55-431B-956D-F6A64C6BC5F8Q58575843-F95C173E-434F-4F99-A62B-64413E64C5C9Q58767936-89EB958B-C26A-4516-AB1E-AD2E2F2A547D
P2860
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Obinutuzumab or Rituximab Plus ...... Diffuse Large B-Cell Lymphoma.
@en
type
label
Obinutuzumab or Rituximab Plus ...... Diffuse Large B-Cell Lymphoma.
@en
prefLabel
Obinutuzumab or Rituximab Plus ...... Diffuse Large B-Cell Lymphoma.
@en
P2093
P50
P356
P1476
Obinutuzumab or Rituximab Plus ...... Diffuse Large B-Cell Lymphoma
@en
P2093
Angelo Michele Carella
Antonio Pinto
David Belada
Günter Fingerle-Rowson
John M Burke
Judit Demeter
Laurie H Sehn
Maurizio Martelli
Michael Wenger
Mikkel Z Oestergaard
P304
P356
10.1200/JCO.2017.73.3402
P407
P577
2017-08-10T00:00:00Z